Khandelwal Laboratories Private Limited

Khandelwal Laboratories Private Limited (KLab) is a privately held pharmaceutical company established in 1945, headquartered in Mumbai, Maharashtra, India. The company specializes in the research and development, manufacturing, distribution, marketing, and licensing of patented pharmaceutical formulations, novel drug delivery systems (NDDS), niche active pharmaceutical ingredients (APIs), and chiral intermediates. KLab has a significant presence in the Indian market, particularly in oncology, antibiotics, pain, and spasm management sectors.

As of the latest available data, KLab's authorized and paid-up capital stands at ₹50 million (approximately $625,000 USD). The company employs over 1,000 individuals across its operations. Its registered office is located at 79/87 D. Lad Path, Kala Chowkie, Mumbai, Maharashtra, 400033, India.

KLab operates three WHO-GMP approved manufacturing facilities in India:

• Thane Facility: Specializes in oncology products, focusing on both formulations and APIs.

• Rudrapur Facility: Dedicated to tablet manufacturing.

• Dadra Facility: Handles injectable formulations.

These facilities enable KLab to produce a diverse range of pharmaceutical products, catering to various therapeutic areas.

The leadership team at KLab includes:

• Mr. Sanjeev Khandelwal: Managing Director

• Mr. S. K. Pai Kakode: Director

• Mr. G. Pinto: Vice President of Finance

• Mrs. P. Omray: Technical Director

• Mr. Lotlikar: Vice President of Quality

• Mr. S. Sharma: International Licensing

This team oversees KLab's strategic direction and operational execution.

KLab's products are subject to regulatory approvals in various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has pursued regulatory filings and approvals to access these markets, though specific details on approvals are not publicly disclosed. KLab's focus on oncology and other therapeutic areas positions it to meet the stringent requirements of these regions.

KLab has expanded its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company has identified and out-licensed products to these regions, leveraging its expertise in oncology and other therapeutic areas. While specific details on WHO prequalification are not available, KLab's strategic initiatives suggest efforts to enhance access to these markets.

KLab's geographic strategy involves a diversified approach, focusing on both domestic and international markets. The company's significant export value of $1.6 million USD across 241 shipments indicates a strong international presence. However, the portfolio concentration, with the top five products accounting for 90.3% of exports, suggests a reliance on a limited product range. This concentration may pose risks if market dynamics shift.

Specific details regarding KLab's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on oncology and other therapeutic areas suggests potential engagement with the FDA, but without explicit information, a comprehensive assessment cannot be made.

KLab's manufacturing facilities are WHO-GMP approved, indicating compliance with international standards for Good Manufacturing Practices. However, specific details regarding EU GMP certificates and EDQM status are not publicly disclosed. The company's focus on oncology and other therapeutic areas suggests potential alignment with EU standards, but without explicit information, a comprehensive assessment cannot be made.

KLab holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers. The company has also obtained export No Objection Certificates (NOCs), facilitating its international trade activities. These regulatory approvals underscore KLab's compliance with Indian pharmaceutical regulations.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to KLab by regulatory authorities. This absence suggests a favorable regulatory standing, though it is advisable to consult the latest regulatory databases for the most current information.

KLab operates in a competitive landscape, particularly in the oncology and generic pharmaceutical sectors. While specific competitors are not identified in the available data, the company's focus on oncology products positions it against both domestic and international players. The market share distribution of KLab's top five products indicates a competitive presence, though the high portfolio concentration may impact its competitive positioning.

KLab's key differentiators include its extensive experience since 1945, a strong focus on oncology products, and a significant number of patents granted or pending. The company's WHO-GMP approved manufacturing facilities and its ability to provide contract manufacturing for over 10 companies further enhance its competitive edge.

KLab's current strategic direction emphasizes the development and marketing of generic pharmaceutical formulations, with a strong focus on oncology products. The recent acquisition of its non-oncology business by Aurobindo Pharma Limited's subsidiary, Auro Pharma Limited, on January 1, 2026, indicates a strategic shift. This move allows KLab to concentrate more on its oncology portfolio, potentially strengthening its position in this therapeutic area.

KLab has a track record of consistent export volume, with a total export value of $1.6 million USD across 241 shipments. The company's portfolio concentration, with the top five products accounting for 90.3% of exports, suggests a focused approach. While this concentration may pose risks, KLab's established presence in oncology and other therapeutic areas indicates reliability as a supplier.

Importers should verify the following certifications when considering KLab as a supplier:

• WHO-GMP Certification: To ensure compliance with international manufacturing standards.

• EU GMP Certification: To confirm adherence to European manufacturing standards.

• FDA Facility Registration: To ascertain eligibility for exporting to the United States.

• ISO Certifications: To evaluate the company's quality management systems.

Verification can be conducted through official regulatory bodies or by requesting copies of the certifications directly from KLab.

When conducting due diligence on KLab, consider the following steps:

• Verify Regulatory Certifications: Ensure all relevant certifications are current and valid.

• Assess Financial Health: Review the latest financial statements to evaluate profitability and stability.

• Evaluate Product Portfolio: Analyze the diversity and market performance of KLab's product offerings.

• Review Supply Chain Practices: Assess the reliability and efficiency of KLab's supply chain operations.

• Check for Regulatory Compliance: Confirm adherence to all applicable regulatory requirements in target markets.

Red flags to watch for include expired certifications, inconsistent financial performance, and any history of regulatory non-compliance. Recommended pre-order checks involve verifying the authenticity of certifications and conducting a thorough background check on the company's operational history.